Confirmed Control Closed Transaction verified gastrointestinal pharmaceuticalsspecialty pharmaceuticals
Sucampo Pharmaceuticals, Inc. acquired by Mallinckrodt
Mallinckrodt acquired Sucampo Pharmaceuticals, Inc., a gastrointestinal pharmaceuticals brand, on Feb 13, 2018.
Transaction summary
- Target
- Sucampo Pharmaceuticals, Inc.
- Acquirer
- Mallinckrodt
- Seller
- -
- Announced
- 2017-12-26
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
USD 1.2B
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
4.6x
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- BioPharma Dive, Fierce Pharma, BioSpace, Bloomberg and pharmaphorum reported a USD 1.2bn deal; a Wall Street Journal headline gave about USD 840m, so the basis of the value is unclear. The 4.6x revenue multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the revenue and period behind it are not stated.
Source summary
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc. - PR Newswire
Confirmed